Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 23 April, 2024|Author: Getaka | Social: X Twitter Profile
Stock Ticker - BSE: 506260 | NSE: ANUHPHR

Fundamental Analysis of Anuh Pharma Ltd

Basic Stock Data

Last Updated: April 23, 2024, 1:30 pm

Market Cap 1,186 Cr.
Current Price 237
High / Low265/86.0
Stock P/E21.8
Book Value 51.2
Dividend Yield0.85 %
ROCE19.1 %
ROE14.5 %
Face Value 5.00

Data Source: screener.in

Competitors of Anuh Pharma Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
BDH Industries Ltd 175 Cr. 303372/12419.8 98.21.32 %20.4 %15.9 % 10.0
Panacea Biotec Ltd 847 Cr. 138202/114 1380.00 %10.3 %10.9 % 1.00
Torrent Pharmaceuticals Ltd 89,299 Cr. 2,6372,746/1,59862.4 1980.83 %19.8 %20.0 % 5.00
Chandra Bhagat Pharma Ltd 86.6 Cr. 115160/80.074.1 37.30.00 %7.13 %3.36 % 10.0
Amerise Biosciences Ltd 4.17 Cr. 0.630.93/0.54 0.820.00 %2.12 %2.15 % 1.00
Industry Average18,082.35 Cr638.7331.2694.460.43%11.95%10.46%5.40

Quarterly Result

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Sales9897117109132129116115139157161150172
Expenses929310996120115105102126143148132148
Operating Profit64812121411131214141824
OPM %7%4%7%11%9%11%10%12%9%9%9%12%14%
Other Income3222011221324
Interest00001-00000000
Depreciation4433332222222
Profit before tax5271191210131213151825
Tax %11%46%21%22%16%26%24%23%23%25%24%23%24%
Net Profit416979710910121419
EPS in Rs0.830.181.121.721.491.781.461.981.861.922.342.763.81

Last Updated: April 10, 2024, 6:02 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: April 6, 2024, 1:41 pm

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales226243266284326206238321307432487527640
Expenses209225242253289183220291284387439476570
Operating Profit17182431382318302345475270
OPM %7%7%9%11%12%11%8%9%8%10%10%10%11%
Other Income424548754115610
Interest1111110112210
Depreciation1223222271512109
Profit before tax18182532382823321939394771
Tax %29%29%31%31%32%27%29%28%25%26%22%24%
Net Profit13131822262017231428313654
EPS in Rs2.562.503.514.395.154.003.304.662.865.686.107.2210.83
Dividend Payout %36%40%37%27%24%31%42%29%48%26%29%28%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2012-20132013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-2023
YoY Net Profit Growth (%)0.00%38.46%22.22%18.18%-23.08%-15.00%35.29%-39.13%100.00%10.71%16.13%
Change in YoY Net Profit Growth (%)0.00%38.46%-16.24%-4.04%-41.26%8.08%50.29%-74.42%139.13%-89.29%5.41%

Growth

Compounded Sales Growth
10 Years:8%
5 Years:17%
3 Years:20%
TTM:28%
Compounded Profit Growth
10 Years:10%
5 Years:19%
3 Years:35%
TTM:53%
Stock Price CAGR
10 Years:25%
5 Years:30%
3 Years:28%
1 Year:168%
Return on Equity
10 Years:14%
5 Years:13%
3 Years:14%
Last Year:14%

Last Updated: April 16, 2024, 11:39 am

Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital4444131313131325252525
Reserves65718297107128137152150166189216232
Borrowings110020244514418
Other Liabilities4960776771485771119128129163135
Total Liabilities119136163168193189209240326333347405400
Fixed Assets810129181717218471615352
CWIP33000063400001
Investments33192743437066398031439180
Other Assets76104124116131101120147163230243261267
Total Assets119136163168193189209240326333347405400

Reserves and Borrowings Chart

Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 92151916262749-192954
Cash from Investing Activity 24-5-12-5-2023-7752-8-43
Cash from Financing Activity -11-6-8-8-9-4-5-722-33-19-12
Net Cash Flow0-02-122-13-502-2

Free Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Free Cash Flow16.0017.0024.0031.0036.0023.0016.0026.00-22.0031.0043.0051.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days63821028884100109859690102118
Inventory Days244333273572646498907766
Days Payable5786102797710210589166133117139
Cash Conversion Cycle313933364270686128486246
Working Capital Days324542435179837044687061
ROCE %26%26%31%33%35%19%14%19%10%16%18%19%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Promoters70.47%70.43%70.43%70.45%70.43%70.59%70.59%70.59%70.59%70.59%70.59%69.93%
Public29.53%29.57%29.57%29.55%29.56%29.42%29.41%29.40%29.40%29.39%29.40%30.05%
No. of Shareholders19,44222,45722,77921,50021,12320,74020,45220,47019,96919,42319,06620,520

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
FaceValue5.005.005.005.005.00
Basic EPS (Rs.)7.226.105.675.719.33
Diluted EPS (Rs.)7.226.105.675.719.33
Cash EPS (Rs.)9.158.488.688.529.99
Book Value[Excl.RevalReserv]/Share (Rs.)48.1442.6638.0464.7465.69
Book Value[Incl.RevalReserv]/Share (Rs.)48.1442.6638.0464.7465.69
Dividend / Share (Rs.)2.001.751.502.752.75
Revenue From Operations / Share (Rs.)105.2697.1186.20122.51127.98
PBDIT / Share (Rs.)11.4510.3911.0010.7713.66
PBIT / Share (Rs.)9.528.007.997.9613.00
PBT / Share (Rs.)9.477.817.697.6412.93
Net Profit / Share (Rs.)7.226.105.675.719.32
PBDIT Margin (%)10.8710.6912.768.7810.67
PBIT Margin (%)9.048.239.276.4910.15
PBT Margin (%)8.998.038.926.2410.10
Net Profit Margin (%)6.856.276.584.667.28
Return on Networth / Equity (%)14.9914.2914.918.8114.19
Return on Capital Employeed (%)19.5718.5320.7312.1819.68
Return On Assets (%)8.938.808.544.389.72
Total Debt / Equity (X)0.000.010.070.270.02
Asset Turnover Ratio (%)1.401.431.311.081.43
Current Ratio (X)1.911.981.701.372.03
Quick Ratio (X)1.461.371.120.991.46
Inventory Turnover Ratio (X)4.944.364.534.596.57
Dividend Payout Ratio (NP) (%)24.2324.590.0096.3329.48
Dividend Payout Ratio (CP) (%)19.1117.670.0064.5827.53
Earning Retention Ratio (%)75.7775.410.003.6770.52
Cash Earning Retention Ratio (%)80.8982.330.0035.4272.47
Interest Coverage Ratio (X)262.7754.1636.8834.06200.20
Interest Coverage Ratio (Post Tax) (X)166.6632.8020.0319.06137.64
Enterprise Value (Cr.)392.34417.88446.02334.07331.66
EV / Net Operating Revenue (X)0.740.851.031.091.03
EV / EBITDA (X)6.848.038.0912.389.69
MarketCap / Net Operating Revenue (X)0.750.881.050.951.06
Retention Ratios (%)75.7675.400.003.6670.51
Price / BV (X)1.652.012.371.802.06
Price / Net Operating Revenue (X)0.750.881.050.951.06
EarningsYield0.090.070.060.040.06

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value: 163.22

The stock is overvalued by 31.13% compared to the current price ₹237

Calculation basis:

  • Fair value = (P/E Ratio * (Return on Equity / 100) * Book Value) * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 22.17%, which is a positive sign.
  2. The company has higher reserves (137.85 cr) compared to borrowings (6.31 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (346.38 cr) and profit (33.00 cr) over the years.
  1. The stock has a high average Working Capital Days of 57.33, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 47.00, which may not be favorable.

Stock Analysis

  • Based on the analysis of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Anuh Pharma Ltd:
    1. Net Profit Margin: 6.85% (Higher values are generally favorable)
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 19.57% (Industry Average ROCE: 11.95%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 14.99% (Industry Average ROE: 10.46%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 166.66 (Higher values, preferably > 2, are recommended)
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.46 (Higher values, preferably > 1, are recommended)
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 21.8 (Industry average Stock P/E: 31.26)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.00 (Lower values, preferably < 1, are preferred)
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    While these metrics suggest potential opportunity, it's essential to conduct thorough research or seek advice from financial experts before making any investment decisions.
    Stock Rating: ★★★★★

About the Company

Anuh Pharma Ltd. is a Public Limited Listed company incorporated on 19/02/1960 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24230MH1960PLC011586 and registration number is 011586. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 486.65 Cr. and Equity Capital is Rs. 25.06 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
Pharmaceuticals3-A, Shivsagar Estate, Mumbai Maharashtra 400018anuh@sk1932.com
http://www.anuhpharma.com
Management
NamePosition Held
Mr. Jasvantlal ShahChairman & Ind.Director
Mr. Bipin N ShahVice Chairman
Mr. Ritesh B ShahJoint Managing Director
Mr. Vivek B ShahJoint Managing Director
Mr. Arun TodarwalIndependent Director
Mr. Sandeep JoshiIndependent Director
Mr. Harmanbhai PatelIndependent Director
Dr.(Ms.) Mita DixitIndependent Director
Mr. Ketan ShahDirector
Mr. Bharat ShahDirector
Mr. Samir ShahDirector

Anuh Pharma Ltd. Share Price Update

Share PriceValue
Today₹237.00
Previous Day₹240.80

FAQ

What is the latest fair value of Anuh Pharma Ltd?

The latest fair value of Anuh Pharma Ltd is ₹163.22.

What is the Market Cap of Anuh Pharma Ltd?

The Market Cap of Anuh Pharma Ltd is 1,186 Cr..

What is the current Stock Price of Anuh Pharma Ltd as on 23 April 2024?

The current stock price of Anuh Pharma Ltd as on 23 April 2024 is 237.

What is the High / Low of Anuh Pharma Ltd stocks in FY 2024?

In FY 2024, the High / Low of Anuh Pharma Ltd stocks is ₹265/86.0.

What is the Stock P/E of Anuh Pharma Ltd?

The Stock P/E of Anuh Pharma Ltd is 21.8.

What is the Book Value of Anuh Pharma Ltd?

The Book Value of Anuh Pharma Ltd is 51.2.

What is the Dividend Yield of Anuh Pharma Ltd?

The Dividend Yield of Anuh Pharma Ltd is 0.85 %.

What is the ROCE of Anuh Pharma Ltd?

The ROCE of Anuh Pharma Ltd is 19.1 %.

What is the ROE of Anuh Pharma Ltd?

The ROE of Anuh Pharma Ltd is 14.5 %.

What is the Face Value of Anuh Pharma Ltd?

The Face Value of Anuh Pharma Ltd is 5.00.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Anuh Pharma Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE